The ATAD3A Knockout Ca Ski Polyclonal Cells constitute a CRISPR/Cas9-edited polyclonal population derived from the Ca Ski cervical carcinoma cell line, engineered for targeted disruption of the ATAD3A gene. This knockout model provides a loss-of-function system to interrogate the role of ATAD3A in mitochondrial dynamics, cholesterol trafficking, and apoptotic regulation. As a polyclonal pool, the product retains genetic heterogeneity, enabling robust population-level studies without clonal artifacts. Researchers can utilize these cells for a wide range of functional assays to dissect ATAD3A-dependent signaling networks in a disease-relevant cellular context.
The parental Ca Ski cell line originates from a metastasis of a cervical carcinoma to the small intestine and is characterized by integrated HPV16 DNA and an adherent epithelial morphology. These cells endogenously express the viral oncoproteins E6 and E7, which disrupt p53 and retinoblastoma tumor suppressor pathways, respectively, and drive oncogenic transformation. Ca Ski cells are extensively employed as a model for HPV-positive cervical cancer, including studies on tumor progression, metastasis, and therapeutic resistance. Their well-documented genomic background makes them particularly suitable for CRISPR/Cas9-mediated gene editing to explore molecular mechanisms underlying cervical carcinogenesis.
ATAD3A encodes a mitochondrial inner membrane AAA ATPase that serves as a critical scaffold for cristae architecture and cholesterol homeostasis through interactions with the MICOS complex and SAM50. The protein functions downstream of transcriptional regulators MYC and E2F1, and its activity is modulated by HPV E6/E7 oncoproteins and growth factor signaling pathways. ATAD3A regulates mTORC1 activity and mitochondrial nucleoid organization, and it interacts with key mitochondrial proteins including VDAC, PINK1, and ATAD3B. Disruption of ATAD3A affects downstream effectors such as the pro-apoptotic factors BAX and BAK, the mitochondrial fission regulator DRP1, and the cholesterol transport protein STAR, thereby impacting mitochondrial integrity and cell survival.
In the Ca Ski cervical cancer model, ATAD3A knockout disrupts mitochondrial ultrastructure, impairs mTOR signaling, and sensitizes cells to intrinsic apoptosis, potentially diminishing tumorigenic capacity. The HPV16-positive background is particularly relevant, as viral oncoproteins may intersect with ATAD3A-dependent pathways to alter mitochondrial metabolism and apoptotic thresholds. This knockout model enables detailed investigation of how mitochondrial dysfunction contributes to HPV-driven malignancy, chemotherapy resistance, and metabolic reprogramming in cervical carcinoma. It provides a physiologically relevant platform to assess the interplay between viral transformation and mitochondrial regulation.
Typical research applications include elucidation of mitochondrial-nuclear communication, screening for ATAD3A-targeted therapies, and mechanistic studies of HPV-induced mitochondrial alterations. Representative assays compatible with these cells encompass western blotting, RT-qPCR, immunofluorescence with MitoTracker staining, flow cytometry for annexin V/PI apoptosis analysis, colony formation, migration and invasion assays, Seahorse metabolic flux analysis, co-immunoprecipitation of ATAD3A complexes, and cholesterol quantification. These applications support both foundational discovery and translational oncology research. For comprehensive technical information, please contact Ascent Research.
